Improving efficacy and toxicity reporting - and treatment insights from an oncologist patient
Improving efficacy and toxicity reporting - and treatment insights from an oncologist patient
WCLC 2025: Latest in EGFR positive NSCLC
Dose escalation of RG6344 demonstrates safety and promising activity in BRAF V600E solid tumours
Treatment management of favourable risk and very favourable risk patients
Breast cancer survivorship
Burden and trends of breast cancer worldwide: Opportunities for prevention?
Managing cardiotoxicities for RCC treatment – Cardiologist’s perspective
Key insights from lung cancer research at ASCO 2025
ASCO 2025: Importance of early testing in metastatic prostate cancer
Nivolumab plus ipilimumab vs gemcitabine-carboplatin in cisplatin-ineligible metastatic urothelial carcinoma
ctDNA-guided chemo escalation does not improve recurrence-free survival in stage III colon cancer
QoL maintained with sasanlimab plus BCG in high-risk, BCG-naive NMIBC